News and Insights | Scrip | Pharma intelligence

From licensing, to clinical trials, to competitor activity – you’ll stay up to date on news worldwide thanks to our global team of 60+ journalists. We go beyond headlines too, with access to key decision-makers and best-in-class proprietary data.

How it works

You’ll get business-critical market and company intelligence from our network of analysts, journalists and key opinion leaders. They cover companies from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and fields including cancer, cardiovascular, diabetes, dermatology, influenza and oncology.

How Scrip can help

Understand what’s behind the headlines – we focus on the strategic implications of global pharma news so you can see what developments mean for your business.

Scrip

Guide To The Turbulent Times At The Top of Teva

By Kevin Grogan 21 Jul 2017

While the rumor mill continues to turn over Pascal Soriot jumping ship from AstraZeneca to Teva.

Scrip

AstraZeneca Under Soriot: Progress Report

By Eleanor Malone 21 Jul 2017

Last week, AstraZeneca's CEO Pascal Soriot was rumored to be preparing for a move to run Teva Pharmaceutical Industries. This week, he's rumored to be staying put.

Scrip

Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes

By Mandy Jackson 21 Jul 2017

A legal settlement with BioMarin means that Sarepta doesn't have to worry anymore.

Scrip

As Digital Channels Grow In Importance, AZ, Lilly, GSK Seen As Key Engagers

By Anju Ghangurde 18 Jul 2017

Digital physician engagement channels appear to be closing in on the traditional face-to-face approach.

Scrip

Top Pharma Firms' Sales At $351bn By 2026

By Sten Stovall 18 Jul 2017

Datamonitor Healthcare's latest sector analysis indicates that the pharma industry's 10 biggest companies.

Scrip

Critical Clinical Trial Updates Expected in 3Q

By Lucie Ellis 11 Jul 2017

Ten clinical trial data readouts to watch for in the third quarter of 2017.

Scrip

A Look At Korea's Alzheimer's Disease

By Jung Won Shin 11 Jul 2017

While rising dementia populations are a worldwide problem, South Korea has to pay particularly close attention.

Scrip

Under Sanpower, Can Provenge Finally Have A Happy Ending?

By Emily Hayes 05 Jul 2017

Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano.

Scrip

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

By Joseph Haas 05 Jul 2017

Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.

Scrip

Podcast: Scaling Up Your Business

27 Jun 2017

BIO International 2017 discussion: growing a biotech business.

Scrip

Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

By Sten Stovall 26 Jun 2017

Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis.

Scrip

AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU

By Lucie Ellis 26 Jun 2017

AbbVie and Gilead's latest hepatitis C therapies are anticipated to win positive recommendations for approval in Europe.

Scrip

After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics

By Joseph Haas 20 Jun 2017

A PwC report on medical cost trends projects that while US health care cost-growth has plateaued, several inflationary factors remain.

Scrip

Generic Drug Pricing Transparency Could Reduce Spending, Study Says

By Jessica Merrill 20 Jun 2017

Every $1 reduction in the average reimbursement for a generic prescription would reduce US healthcare spending by $4bn, according to a study from Brookings.